A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy

M. Tishler, D. Caspi, Z. Halperin, M. Baratz, M. Moshkowitz, M. Yaron

Research output: Contribution to journalArticlepeer-review

Abstract

Baseline and sequential liver biopsies were performed in ten patients with rheumatoid arthritis (RA) treated with methotrexate (MTX) for more than 4 years. Liver biopsies were performed in all patients before the initiation of MTX therapy and were repeated after reaching a cumulative dose of 1500 mg or more. In four patients a third biopsy was performed 3 years after the first one. No significant worsening of hepatic architecture was found in any of our patients after 4 to 71/2 years of MTX therapy. No correlations between histologic findings and various clinical or pharmacological variables could be found. Our results suggested that prolonged MTX administration in RA patients did not cause severe hepatic abnormalities.

Original languageEnglish
Pages (from-to)39-41
Number of pages3
JournalRheumatology International
Volume12
Issue number1
DOIs
StatePublished - Mar 1992
Externally publishedYes

Keywords

  • Hepatotoxicity
  • Methotrexate
  • Rheumatoid arthritis

Fingerprint

Dive into the research topics of 'A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy'. Together they form a unique fingerprint.

Cite this